Casuística
Experiencia con sunitinib en cáncer de próstata metastásico hormonorresistente sin respuesta a docetaxel
Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel
J.M. Gasenta,
, E. Grandeb, J. Casinelloc, M. Provenciod, J.B. Laforgae, V. Alberolaf
Autor para correspondencia
a Servicio de Oncología Médica, Hospital de Denia, Alicante, España
b Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, España
c Servicio de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
d Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Madrid, España
e Servicio de Anatomía Patológica, Hospital de Denia, Alicante, España
f Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, España
Leído
2841
Vecesse ha leído el artículo
588
Total PDF
2253
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 5 | 5 |
| 2025 11 | 0 | 2 | 2 |
| 2025 10 | 0 | 3 | 3 |
| 2025 9 | 0 | 2 | 2 |
| 2025 8 | 0 | 3 | 3 |
| 2025 7 | 0 | 1 | 1 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 1 | 1 |
| 2025 4 | 0 | 1 | 1 |
| 2025 3 | 0 | 3 | 3 |
| 2025 1 | 0 | 1 | 1 |
| 2024 11 | 0 | 2 | 2 |
| 2024 9 | 0 | 1 | 1 |
| 2024 8 | 0 | 3 | 3 |
| 2024 7 | 0 | 4 | 4 |
| 2024 6 | 0 | 1 | 1 |
| 2024 5 | 0 | 1 | 1 |
| 2024 4 | 0 | 1 | 1 |
| 2024 3 | 0 | 2 | 2 |
| 2024 2 | 0 | 1 | 1 |
| 2023 12 | 0 | 1 | 1 |
| 2023 11 | 0 | 2 | 2 |
| 2023 10 | 0 | 3 | 3 |
| 2023 7 | 0 | 2 | 2 |
| 2023 6 | 0 | 4 | 4 |
| 2023 3 | 1 | 5 | 6 |
| 2023 2 | 0 | 4 | 4 |
| 2022 1 | 0 | 1 | 1 |
| 2022 12 | 0 | 1 | 1 |
| 2022 11 | 0 | 2 | 2 |
| 2022 10 | 0 | 1 | 1 |
| 2022 9 | 0 | 1 | 1 |
| 2022 7 | 0 | 1 | 1 |
| 2022 6 | 0 | 1 | 1 |
| 2022 5 | 0 | 1 | 1 |
| 2022 4 | 0 | 4 | 4 |
| 2022 3 | 0 | 2 | 2 |
| 2022 2 | 0 | 1 | 1 |
| 2021 1 | 0 | 3 | 3 |
| 2021 11 | 0 | 1 | 1 |
| 2021 10 | 0 | 2 | 2 |
| 2021 9 | 0 | 1 | 1 |
| 2021 8 | 0 | 3 | 3 |
| 2021 7 | 0 | 6 | 6 |
| 2021 6 | 0 | 3 | 3 |
| 2021 5 | 0 | 1 | 1 |
| 2021 4 | 0 | 1 | 1 |
| 2021 2 | 0 | 1 | 1 |
| 2020 1 | 0 | 2 | 2 |
| 2020 9 | 0 | 1 | 1 |
| 2020 6 | 0 | 2 | 2 |
| 2020 3 | 0 | 3 | 3 |
| 2020 1 | 0 | 2 | 2 |
| 2019 12 | 0 | 1 | 1 |
| 2019 11 | 0 | 2 | 2 |
| 2019 7 | 0 | 2 | 2 |
| 2019 6 | 0 | 5 | 5 |
| 2019 5 | 0 | 17 | 17 |
| 2019 2 | 0 | 1 | 1 |
| 2019 1 | 0 | 1 | 1 |
| 2018 8 | 1 | 0 | 1 |
| 2018 2 | 0 | 1 | 1 |
| 2018 1 | 4 | 2 | 6 |
| 2017 12 | 8 | 0 | 8 |
| 2017 11 | 4 | 0 | 4 |
| 2017 10 | 8 | 2 | 10 |
| 2017 9 | 12 | 2 | 14 |
| 2017 8 | 4 | 4 | 8 |
| 2017 7 | 9 | 3 | 12 |
| 2017 6 | 13 | 6 | 19 |
| 2017 5 | 14 | 4 | 18 |
| 2017 4 | 10 | 9 | 19 |
| 2017 3 | 14 | 5 | 19 |
| 2017 2 | 9 | 3 | 12 |
| 2016 1 | 5 | 4 | 9 |
| 2016 12 | 27 | 19 | 46 |
| 2016 11 | 32 | 20 | 52 |
| 2016 10 | 29 | 22 | 51 |
| 2016 9 | 27 | 7 | 34 |
| 2016 8 | 23 | 4 | 27 |
| 2016 7 | 28 | 2 | 30 |
| 2016 6 | 29 | 27 | 56 |
| 2016 5 | 25 | 16 | 41 |
| 2016 4 | 19 | 11 | 30 |
| 2016 3 | 29 | 20 | 49 |
| 2016 2 | 20 | 22 | 42 |
| 2015 1 | 22 | 15 | 37 |
| 2015 12 | 22 | 14 | 36 |
| 2015 11 | 18 | 10 | 28 |
| 2015 10 | 23 | 15 | 38 |
| 2015 9 | 18 | 7 | 25 |
| 2015 8 | 20 | 9 | 29 |
| 2015 7 | 13 | 11 | 24 |
| 2015 6 | 5 | 7 | 12 |
| 2015 5 | 8 | 7 | 15 |
| 2015 4 | 23 | 14 | 37 |
| 2015 3 | 16 | 9 | 25 |
| 2015 2 | 6 | 4 | 10 |
| 2015 1 | 31 | 12 | 43 |
| 2014 12 | 34 | 11 | 45 |
| 2014 11 | 26 | 5 | 31 |
| 2014 10 | 50 | 14 | 64 |
| 2014 9 | 40 | 4 | 44 |
| 2014 8 | 17 | 3 | 20 |
| 2014 7 | 31 | 6 | 37 |
| 2014 6 | 43 | 9 | 52 |
| 2014 5 | 25 | 4 | 29 |
| 2014 4 | 12 | 6 | 18 |
| 2014 3 | 21 | 4 | 25 |
| 2014 2 | 20 | 8 | 28 |
| 2014 1 | 22 | 3 | 25 |
| 2013 12 | 20 | 3 | 23 |
| 2013 11 | 20 | 8 | 28 |
| 2013 10 | 20 | 5 | 25 |
| 2013 9 | 12 | 4 | 16 |
| 2013 8 | 13 | 4 | 17 |
| 2013 7 | 7 | 0 | 7 |
| 2010 1 | 1191 | 0 | 1191 |
Mostrar todo
